20 citations
,
March 1990 in “Archives of Dermatology” Nonimmunosuppressive cyclosporines might treat skin diseases by affecting cell growth.
September 2025 in “Acta Dermato Venereologica” Baricitinib can help improve hair loss and skin color issues in people with Down syndrome.
280 citations
,
January 2004 in “The EMBO Journal” AGC2-1 protein is essential for root hair growth in Arabidopsis.
June 2025 in “Journal of Education Health and Sport” Oral JAK inhibitors show promise for treating alopecia areata but have challenges like relapse and side effects.
81 citations
,
February 2019 in “Experimental & Molecular Medicine” PAK4 is crucial in cancer progression, brain development, and could be a therapeutic target, especially through the PAK4-CREB axis.
97 citations
,
January 2020 in “Advances in chronic kidney disease” Calcineurin inhibitors, used in kidney transplants, can cause a wide range of side effects including kidney damage and other health issues.
February 2017 in “Cancer Research” Topical calcitriol appears safe and may reduce hair loss during chemotherapy.
6 citations
,
October 2014 in “Experimental Dermatology” Prostaglandins and the enzyme AKR1C3 could play a role in skin cancer and hair loss, and further research is needed to understand these mechanisms.
30 citations
,
March 2007 in “Expert opinion on drug safety” Cetuximab often causes skin rashes, and managing these is important for cancer treatment.
October 2015 in “Elsevier eBooks” Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.
December 2025 in “Biomolecules” Compound 7p shows strong potential as an anticancer agent.
January 2026 in “Biomolecules” TSC22D genes are key in metabolic diseases and cancer, offering potential as treatment targets.
13 citations
,
June 2023 in “Frontiers in Pharmacology” Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.
87 citations
,
March 2013 in “Expert Review of Anticancer Therapy” Afatinib often causes skin problems that need proactive management.
1 citations
,
April 2004 in “Cancer” Imatinib mesylate can cause skin lightening, especially in Chinese patients, due to its effect on pigment production.
December 2024 in “Naunyn-Schmiedeberg s Archives of Pharmacology” Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
November 2025 in “Journal of the European Academy of Dermatology and Venereology” JAK inhibitors may reduce depression in people with alopecia areata.
2 citations
,
September 2024 in “Internal Medicine Journal” Upadacitinib helped regrow hair and maintain ulcerative colitis remission.
Activating certain cells in hair follicles can prevent hair loss caused by cancer treatments.
1 citations
,
April 2020 in “Journal of the Endocrine Society” Immunotherapy with pembrolizumab significantly reduced cancer in a young woman with adrenocortical carcinoma.
65 citations
,
November 2013 in “The EMBO Journal” HDAC1 is crucial for skin development and preventing tumors.
11 citations
,
December 2013 in “Clinical and Experimental Dermatology” Sorafenib often causes skin side effects, indicating effective cancer treatment.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.
26 citations
,
October 2019 in “JNCI Cancer Spectrum” Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Ritlecitinib effectively regrows and maintains scalp, eyebrow, and eyelash hair in alopecia areata patients.
15 citations
,
February 2017 in “Nursing Clinics of North America” Targeted cancer therapies can cause skin side effects, which should be treated early to help patients' quality of life and treatment adherence.
March 2026 in “Immunological Medicine” Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
May 2026 in “Frontiers in Pharmacology” Long-term use of 5α-reductase inhibitors may improve survival in men with kidney cancer.
25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.